AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Summit Therapeutics Inc. (SMMT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23.04

1.44 (6.67%)

At close: Feb 20, 2025, 3:59 PM

22.99

-0.22%

After-hours: Feb 20, 2025, 06:30 PM EST

undefined% (undefined)

Bid	22.99
Market Cap	16.98B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.23
PE Ratio (ttm)	-100.17
Forward PE	n/a
Analyst	Buy

Ask	23.5
Volume	2,844,874
Avg. Volume (20D)	2,180,157
Open	21.52
Previous Close	21.60
Day's Range	21.46 - 23.08
52-Week Range	2.10 - 33.89
Beta	undefined

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, fo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 5, 2015

Employees 105

Stock Exchange NASDAQ

Ticker Symbol SMMT

Website https://www.summittxinc.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for SMMT stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 38.89% from the latest price.

Buy 71.43%

Hold 14.29%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago

+16.13%

Summit Therapeutics shares are trading higher. HC ... Unlock content with Pro Subscription

1 month ago

+3.63%

Summit Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and a $35 price target.

News

3 days ago · fool.com

3 Stocks That Could Trounce the Market in 2025

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

6 days ago · businesswire.com

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...

1 week ago · fool.com

Is Summit Therapeutics a Millionaire Maker?

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical pro...

1 week ago · fool.com

2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%).

3 weeks ago · fool.com

Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?

It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could dissi...

4 weeks ago · fool.com

3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how analysts view a given stock.

1 month ago · fool.com

Why Summit Therapeutics Stock Is Jumping Today

Shares of Summit Therapeutics (SMMT 15.40%) had jumped 14.3% at 11:31 a.m. ET on Tuesday.

1 month ago · seekingalpha.com

Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)

Summit Therapeutics' stock rose 888% since September 2023, driven by positive Phase 3 data for ivonescimab showing superior PFS vs Keytruda in NSCLC. Phase 3 HARMONi-2 trial showed 11.14 vs 5.82 month...

1 month ago · fool.com

Why Summit Therapeutics Rocketed 584% in 2024

Shares of biotech Summit Therapeutics (SMMT -8.39%) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence.

1 month ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

Load More News